12.12.2023 13:24:36
|
C4 Therapeutics, Merck Join To Develop Degrader-Antibody Conjugates
(RTTNews) - C4 Therapeutics, Inc. (CCCC) has entered into an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates, an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells. C4T will be responsible for using its TORPEDO platform to develop degrader payloads in the discovery phase. Merck will be responsible for antibody conjugation to create DACs in the discovery phase and for advancing these DAC candidates through preclinical and clinical development as well as commercialization.
C4T will receive a $10 million upfront payment. C4T and Merck will collaborate to develop Degrader-Antibody Conjugates directed to an initial undisclosed oncology target. For Degrader-Antibody Conjugates directed to this initial target, C4T is eligible to receive milestone payments totaling approximately $600 million, as well as tiered royalties on future sales.
The agreement also provides Merck with the option to extend the collaboration to include three additional targets.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
10.03.25 |
Schwacher Handel in New York: Dow Jones schwächelt (finanzen.at) | |
07.03.25 |
Schwacher Handel: Dow Jones liegt mittags im Minus (finanzen.at) | |
07.03.25 |
Impulsarmer Handel in New York: Dow Jones pendelt zum Start des Freitagshandels um seinen Schlusskurs vom Donnerstag (finanzen.at) | |
06.03.25 |
Börse New York: Dow Jones fällt schlussendlich zurück (finanzen.at) | |
04.03.25 |
Dow Jones aktuell: Dow Jones mittags in Rot (finanzen.at) | |
04.03.25 |
Dow Jones 30 Industrial-Titel Merck-Aktie: So viel hätten Anleger mit einem Investment in Merck von vor 5 Jahren verdient (finanzen.at) | |
04.03.25 |
Minuszeichen in New York: Dow Jones zum Start des Dienstagshandels im Minus (finanzen.at) | |
03.03.25 |
Verluste in New York: Dow Jones fällt zum Ende des Montagshandels zurück (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
C4 Therapeutics Inc Registered Shs | 2,16 | -8,47% |
|
Merck Co. | 87,60 | 1,51% |
|